Prescient Therapeutics Investor Briefing
Prescient Therapeutics CEO Steven Yatomi-Clarke is joined by special guest Professor H. Miles Prince, specialist haematologist and principal investigator of the PTX-100 study.
In this session, they discussed:
- The results of the PTX-100 phase 1b trial, which exhibited excellent safety profile with no serious adverse events
- How the trial demonstrated a clinical signal seen in T cell lymphoma (TCL) patients
- How PTX-100 will now progress to an expansion cohort study focussing on TCL with potential for subsequent registration study
Recorded on 30 July 2021 at 11am (AEST)
Featured Speakers
Steven Yatomi-Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.
Professor H. Miles Prince
Specialist Haematologist Epworth Health / Peter MacCallum
Professor Prince is an internationally recognised haematologist; a brilliant mind in the field of blood-related conditions, stem cell research and the study of the immune system – specifically in blood and cancer growth. He is the Director of the Centre for Blood Cell Therapy at Peter MacCallum Cancer Centre and Chairman of the Medical Scientific Advisory Committee to the Myeloma Foundation Australia, amongst other notable roles.
Steven Yatomi-Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.
Professor H. Miles Prince
Specialist Haematologist Epworth Health / Peter MacCallum
Professor Prince is an internationally recognised haematologist; a brilliant mind in the field of blood-related conditions, stem cell research and the study of the immune system – specifically in blood and cancer growth. He is the Director of the Centre for Blood Cell Therapy at Peter MacCallum Cancer Centre and Chairman of the Medical Scientific Advisory Committee to the Myeloma Foundation Australia, amongst other notable roles.
